The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
CellProtect receives EU orphan drug status for the treatment of MM
The European Medicines Agency (EMA) has granted CellProtect orphan drug designation for the treatment of Multiple Myeloma (MM). CellProtect technology is owned by CellProtect Nordic Pharmaceuticals AB (CPNP), and is, in essence, a process by which a patient's own natural killer (NK) cells are removed, activated, and expanded in-vitro. The activated cells, with enhanced immunocompetence, are then transferred back into the patient, enabling more effective killing of tumor cells.
This therapy is being tested in phase I/II clinical trials with MM patients that are being carried out at the Karolinska University Hospital in Sweden, as a supplementary treatment to Autologous Stem Cell Transplant (ASCT). To date, initial results from these trials have been promising, showing a good safety profile and effective outcomes, with the full results due to be published in 2018. This will be welcome news for MM patients who will be hoping to see effective cell therapies move closer to the clinic.